Aprea Therapeutics

Contributing Author

Recent Articles by Aprea Therapeutics

Aug-12	Aprea Therapeutics Announces Second Quarter 2026 Financial Results APRE GlobeNewswire
Jul-30	Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 APRE GlobeNewswire
Jun-01	Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors APRE -8.59% GlobeNewswire
May-13	Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update APRE GlobeNewswire
Apr-21	Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting APRE -7.51% GlobeNewswire
Apr-01	Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement APRE -7.75% GlobeNewswire
Mar-30	Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement APRE +8.20% GlobeNewswire
Mar-30	Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial APRE +8.20% GlobeNewswire
Mar-16	Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update APRE GlobeNewswire
Feb-18	Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial APRE +21.33% GlobeNewswire
Feb-17	Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference APRE GlobeNewswire
Feb-12	Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth APRE GlobeNewswire
Feb-04	Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor APRE GlobeNewswire
Jan-29	Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan APRE -22.78% GlobeNewswire
Jan-29	Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules APRE -22.78% GlobeNewswire
Dec-18	Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 APRE GlobeNewswire
Dec-09	Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules APRE -10.80% GlobeNewswire
Nov-12	Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update APRE GlobeNewswire
Oct-24	Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 APRE -7.89% GlobeNewswire
Oct-15	Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies APRE GlobeNewswire
Oct-14	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics APRE GlobeNewswire
Aug-28	Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference APRE GlobeNewswire
Aug-12	Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update APRE GlobeNewswire
Jun-25	Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center APRE +10.09% GlobeNewswire
May-14	Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update APRE GlobeNewswire

Aprea Therapeutics

Recent Articles by Aprea Therapeutics

Upgrade your Finviz experience